BioSphere expects to commence shipments of Embosphere Microspheres to China in the first quarter of 2008.
Richard Faleschini, president and CEO of BioSphere, said: “We believe that among these covered lives are a large number of patients who have and are being treated for benign and malignant hypervascularized tumors, such as uterine fibroids and hepatocellular carcinoma, respectively. Therefore, we believe that China has the potential to be an attractive market for us, and a catalyst for potential future revenue growth.”